#5 - Anavex Life Sciences (NASDAQ:AVXL)
Small-cap biopharmaceutical companies like Anavex Life Sciences, Inc. (NASDAQ: AVXL) are always about balancing risk and reward. Like many of these companies, Anavex is not only unprofitable; it is still in the pre-revenue stage.
However, there’s a reason why analysts have a consensus price target of $44, a 411% gain from the stock’s price on February 19, 2025. The company’s lead drug candidate is ANAVEX 2-73, which is being tested for the treatment of Alzheimer’s disease, Parkinson’s disease and other diseases of the central nervous system.
If successful, the drug would undoubtedly be a blockbuster. To that end, the stock started to soar in December 2024 when the company announced that the European Medicines Agency (EMA) accepted its application to review ANAVEX 2-73. It’s not the same as getting FDA approval in the United States, but for many traders, it was enough to push the stock higher.
The risk is that the EMA will not approve the application. But if it does, AVXL stock is likely to move significantly higher. Analysts seem to believe this as they maintain their price targets for the stock.
About Anavex Life Sciences
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
More- Current Price
- $8.35
- Consensus Rating
- Buy
- Ratings Breakdown
- 3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $44.00 (426.9% Upside)
